Bilenduke, Emily
Sterrett, John D.
Ranby, Krista W.
Borges, Virginia F.
Grigsby, Jim
Carr, Alaina L.
Kilbourn, Kristin
Lowry, Christopher A.
Funding for this research was provided by:
Cancer Prevention and Control (CPC) Program
Article History
Received: 8 July 2022
Accepted: 5 November 2022
First Online: 15 November 2022
Competing interests
: C.A.L. serves on the Scientific Advisory Board of Immodulon Therapeutics, Ltd., is Cofounder and Chief Scientific Officer of Mycobacteria Therapeutics Corporation, and is a member of the faculty of the Integrative Psychiatry Institute, Boulder, Colorado. The other authors declare no competing interests.